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Abstract
Background: Extended-spectrum β-lactamase (ESBL)-producing bacteria are resistant to several types of antibiotics
excluding carbapenems. A transmissibility of ESBL-producing Enterobacteriaceae would be depending on each
bacterial property, however, that has not been elucidated in clinical setting. In this study, we attempted to identify
the source of an outbreak of ESBL-producing bacteria in a medical oncology and immunology care unit.
Methods: An ESBL-producing Enterobacteriaceae (ESBL-E) outbreak observed between July 2012 and August 2012
in Kagawa University Hospital was surveyed using various molecular microbiology techniques. We used Pulsed-field
gel electrophoresis (PFGE), PCR-based ESBL gene typing, and direct sequence of ESBL gene as molecular microbiology
typing method to distinguish each strain.
Results: The typical prevalence of ESBL-E isolation in the unit was 7.0 per month (1.7 per week). The prevalence
of ESBL-E isolation during the target research period was 20.0 per month (5.0 per week). In total, 19 isolates (11 K.
pneumoniae and 8 E. coli) were obtained from clinical samples, including four control strains (two each of both
bacteria), that were physically different from those obtained from other inpatient units in our hospital. Pulsed-
field gel electrophoresis (PFGE) for K. pneumoniae (digested by XbaI) produced similar patterns excluding one
control strain. PCR classification of the ESBL gene for K. pneumoniae revealed that all strains other than the
control strain carried SHV and CTX-M-9. This result was reconfirmed by direct DNA sequencing. Although the
outbreak of K. pneumoniae was considered to be “clonal,” PFGE and PCR classification of the ESBL genes for
E. coli uncovered at least six different “non-clonal” strains possessing individual ESBL gene patterns. According
to the result of an antibiogram, the pattern of antimicrobial susceptibility was more variable for K. pneumoniae
than for E. coli.
Conclusions: Typing by PFGE and ESBL gene PCR analysis is practical for discriminating various organisms. In
our cohort, two outbreaks were concomitantly spread with different transmission strategies, namely clonal and
non-clonal, in the same unit. This might represent clinical evidence that transmissibility differs according to
the type of strain. We speculated that patient-to-patient transmission of ESBL-E occurred according to the
properties of each individual strain.
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Background
Extended-spectrum β-lactamase (ESBL)-producing bac-
teria are resistant to most beta-lactam antibiotics, includ-
ing penicillins, cephalosporins, and the monobactam.
Consequently, infections caused by ESBL-producing
bacteria are difficult to treat. In addition, there are no
evidence-based guidelines specifying the infection control
for ESBL-producing bacterial outbreak. Therefore, ESBL-
producing bacteria easily disseminate and cause nosoco-
mial infection. Infection control of ESBL-producing
bacteria is important to prevent outbreaks [1].
An outbreak is defined as the increased incidence of
an infectious disease in a specific place during a given
period that exceeds the baseline rate for that place and
period [2]. According to past reports, outbreaks of
ESBL-producing bacteria develop from a single source of
infection related to a unique original source, termed
“clonal” outbreaks [3]. However, “clonal” outbreak is not
the dominant dissemination pattern in limited areas
such as care units in healthcare institutes. Global propa-
gation of ESBL genes has been reported among carriers
of ESBL-producing bacteria in the community, and it is
becoming a general form of bacterial spread [4–6]. In
other words, outbreaks of ESBL-producing bacteria can
be caused by multiple sources, termed “non-clonal” out-
breaks. Opposed to the clonal spread of ESBL-producing
bacteria, non-clonal outbreaks are becoming more
common [7–9]. In addition to the clonality of outbreak
strains, the molecular mechanism of ESBL gene acqui-
sition may contribute to the dynamics of transmission
in the clinical setting [8, 10]. However, differences in
the spread of ESBL-producing bacteria have not been
fully unveiled.
In our institution, we experienced an outbreak of
ESBL-producing bacteria in our medical oncology and
immunology care unit. We attempted to identify the ori-
ginal strains of the first index case of infection to clarify
the source of infection outbreaks and control nosoco-
mial spread; we performed molecular microbiological
analysis of ESBL-E bacteria in our retrospective cohort.
The outbreak comprised a mixture of two types of
ESBL-producing Enterobacteriaceae (ESBL-E), Klebsiella
pneumoniae and Escherichia coli. A main interest of this
research is the mechanism of spread of ESBL-E. Our
hypothesis is ESBL-producing bacteria has a different
transmissibility based on different bacterial properties.
Methods
Patients and method
Between July and August 2012, in the medical oncology
and immunology care unit of our institute (41 beds), 19
strains were obtained from clinical samples during
ESBL-E outbreaks. Strains obtained in the unit included
the samples of all patients who participated in
surveillance during the observed outbreaks. Control
strains were prepared from clinically different isolates
from heterotopy/heterochrony sampling (labeled as © in
Figures). We used the first isolate from each clinical
sample of all individuals for the analysis. Thus, two or
more isolates could be obtained from each individual,
such as one strain from stool and the other from blood.
Our target species were ESBL-E, namely K. pneumoniae
and E. coli [8]. Although we observed the outbreak in
2012, the institutional review board approved our re-
search in 2015.
In this study, we defined two outbreak types according
to the source of infection as follows: 1) outbreak from a
single source (clonal outbreak) and 2) outbreak from
multiple sources (non-clonal outbreak). An outbreak is
defined as an increase in the rate of ESBL-E cases or a
clustering of new cases in a specific place during a given
period. In this report, we defined an unusual increase in
ESBL cases as a repeated isolation of ESBL from the
medical oncology and immunology care unit, with an
incidence ±2 SD over the baseline.
Molecular microbiology methods
Pulsed-field gel electrophoresis (PFGE) typing
Strains isolated from clinical samples were pulsed-
electrophoresed on a degraded field agarose gel. The
Tenover criteria were used for the separation and identi-
fication of each band [2]. Only strains with indistin-
guishable band profiles were considered to represent the
same clone. ESBL-producing K. pneumoniae and E. coli
isolates were aerobically cultured in brain heart infusion
broth (Eiken Chemical Co. Ltd.) for 16 h at 37 °C. PFGE
plugs were prepared using a Gene Path Kit (Bio-Rad)
according to the manufacturer’s instructions. The plugs
were digested overnight with 30 U of Xba I (New England
Biolabs) at 37 °C. The digested DNA bands were separated
on 1.0% agarose gels by PFGE using the CHEFF DR II sys-
tem (Bio-Rad). PFGE was performed under the following
conditions: electric field strength, 6 V/cm; pulse time, 4–
8 s for 9 h followed by 8–50 s for 13 h; and buffer
temperature, 14 °C. After electrophoresis, the gels were
stained with ethidium bromide (0.5 μg/ml).
Antimicrobial susceptibility testing
The antibiotic susceptibility of strains isolated from clin-
ical samples was assessed by microdilution methods
using an IA20MIC mkII system (Koden Industry Co.,
Japan). The following antibiotics were used: piperacillin/
tazobactam (PIPC/TAZ), cefotiam (CTM), ceftazidime
(CAZ), cefoperazone/sulbactam (CPZ/SBT), cefpirome
(CPR), azactam (AZT), minocycline (MINO), imipenem/
cilastatin (IPM/CS), meropenem (MEPM), ciprofloxacin
(CPFX), levofloxacin (LVFX), and amikacin (AMK). Break-
points were adapted according to Clinical and Laboratory
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Standards Institute (CLSI) criteria. Susceptibility was de-
termined by disc diffusion, following the CLSI recommen-
dations for Enterobacteriaceae (CLSI 2010, Performance
Standards for Antimicrobial Susceptibility Testing; Twen-
tieth Informational Supplement, M100-S20, Jan. 2010).
Drug resistance among the ESBL-producing isolates was
assessed by disk dilution methods. Evidence of ESBL pro-
duction was defined as synergy between co-amoxiclav and
at least one of the following antibiotics: cefotaxime (CTX),
CAZ, or CPFX. The minimum inhibitory concentrations
of CTX and CAZ, with and without clavulanic acid
(CVA), were determined subsequently [11].
PCR-based ESBL gene typing
Molecular ESBL typing was performed as described previ-
ously [12]. In detail, ESBL-producing bacteria were
screened by PCR/DNA for the detection of blaTEM,
blaSHV, and blaCTX-M. Subsequently, ESBL genes with spe-
cific CTX-M subtypes (groups 1, 2, 8 and 9) were charac-
terized using multiplex PCR amplification of the DNA
extracted from each strain as previously described [13].
Data collection and ethical issues
We retrospectively obtained patient data from their
medical records. This cohort study was conducted under
the approval of the institutional review board (IRB) of
our institute (IRB approval No. 27-197).
We numbered the strains as an identifier number
which does not compromise patient anonymity.
Results
The typical prevalence of ESBL-E isolation in the unit
was 7.0 per month (1.7 per week). The prevalence of
ESBL-E considered positive instances at all the infection
sites. A different isolate from the same sampling site in
the same individual was not counted double, but a dif-
ferent isolate from the different sampling site in the
same individual was counted as a different event. The
prevalence of ESBL-E isolation during the target re-
search period (July to August 2012) was 20.0 per month
(5.0 per week; Fig. 1). We recognized this is an outbreak
of ESBL-E in the given period. The time course of
ESBL-E isolation in the room is depicted in Fig. 2. Total
19 patients were affected by the outbreak and 15 isolates
were used for our analysis. The patients involved in this
study were 16 females and 3 males. The median age was
65 years (range 25–73 years). The patients’ diseases and
isolation samples were shown in Fig. 2. The median dur-
ation from admission to the day of ESBL-E detection
was 36 days (range 4–191 days). A cluster outbreak was
identified in Room 480, but it was merely a partial
phenomenon. The regional outbreak in Room 480 was
assumed to be due to transmission. The patients in
Room 480 shared a bathroom.
PFGE patterns could not discriminate a series of nine
K. pneumoniae strains from clinical samples (with two
control strains, K10 and K11; Fig. 3a). However, regard-
ing E. coli, all six strains were discriminated as different
strains (with 2 control strains, E8 and E9, Fig. 3b). Next
we examined the susceptibility of sample strains. In
addition, the results of ESBL gene typing were compat-
ible with those of PFGE typing. All ESBL genes extracted
from K. Pneumoniae were categorized in CTX-M-9
excluding one control strain (K10) which had carried
SMV (Table 1). On another, ESBL genes derived from E.
coli strains were varied in each strain with TEM, SMV,
CTX-M-1, CTX-M-2, or CTX-M-9 (Table 1). The result
of an antibiogram were supplied in the supplemental
data (Additional file 1: Table S1). The pattern of anti-
microbial susceptibility was more variable for K. pneu-
moniae than for E. coli.
In totality, the results of PFGE, antimicrobial suscepti-
bility testing, and ESBL gene typing were not consistent
for K. pneumoniae and E. coli. All isolates from K. pneu-
moniae belonged to sequence type (ST) 1308, where
control strain (K2) harbored ST1728. This result was
consistent with the ESBL gene subtypes (CTX-M-9 iden-
tified in K. pneumoniae isolates in our cohort). The out-
break of ST1308 was determined genetically. The
antibiogram pattern varied for K. pneumoniae. The out-
break of ESBL-producing K. pneumoniae could be
judged to have the same source of infection in some
Fig. 1 Frequency of extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) isolation in our unit. The incidence of ESBL-E isolation
in the microbiological laboratory in our institute was determined. Klebsiella pneumoniae is indicated by the gray bar, and Escherichia coli is denoted by
the shadow bar. Only the first microbe isolated from each sample was counted, but the isolation of different specimens in different samples from the
same individual was permitted
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patients, although not all cases in this episode involved
infection with the same strain. For instance, in Room
480, cluster clonal transmission could have easily oc-
curred. Of note, case K7 harbored K. pneumoniae and E.
coli in the oral cavity and stool, respectively. On the
other hand, the isolates from E. coli were genetically dif-
ferent by PFGE and ESBL gene typing. The outbreak of
ESBL-producing E. coli strains did not disseminate from
the same source of infection as K. pneumoniae. Thus,
we concluded that a mixed clonal and non-clonal out-
break had occurred in each strain, respectively.
Discussion
The distinction of strain clonality by antimicrobial sus-
ceptibility testing is difficult. Resistance to multiple clas-
ses of antibiotics is described as multidrug resistance.
Although ESBL exerts a distinctive mechanism for mul-
tidrug resistance, subclasses of multidrug resistance have
not been elucidated. Thus, our original categorization of
drug resistance in this study is not essential, and we con-
sidered the antibiogram result to be supplemental data.
Conversely, PFGE and ESBL gene type was conducted
for ESBL-E strain identification, and we obtained solid
results. These analyses of our cohort identified molecu-
lar similarity in the PFGE patterns of ESBL-producing K.
pneumoniae. Although one of the control strains and
clinically different strains were not distinguishable, we
realized that K. pneumoniae strains were of the same
origin in the cohort. Identification of the source of infec-
tion only based on antimicrobial susceptibility testing in
the clinical laboratory would not be practical. Given the
dissemination of ESBL-producing bacteria and ESBL
gene spread in the community, tracing the source of
infection in ESBL-E outbreaks is not beneficial in
practice. In any case involving ESBL-producing bac-
teria, standard precautions should be taken, but tra-
cing the original index case would not contribute to
clinical decisions.
Fig. 2 A description of the patients and the times at which extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) were isolated
in our unit. Patients’ characteristics (age, gender, and diseases) are shown. A unique strain number was provided according to the room number.
“K” denotes K. pneumoniae isolates, and “E” indicates E. coli isolates. The types of clinical specimens (blood, urine, oral, and stool) are indicated by
red, yellow, green, and brown boxes, respectively. The four control strains, comprising clinically distinct isolates, are shown at the bottom of the
list. The rightmost row (row in dark) presents the results of surveillance performed at the end of the outbreak
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An obvious source of environmental contamination
can be easily detected. In our cohort, the clonal outbreak
was associated with fecal spread in the bathroom. To es-
timate the clonality of an outbreak, the location of the
outbreak is important. Detecting the ESBL source, i.e.,
“looking for the culprit,” may support in infection-control
measures, but it is impossible to achieve complete patient
isolation immediately [10]. Patient-to-patient transmission
of ESBL-E via the hands of healthcare workers in our
unit appeared to be common. Therefore, concomitant
outbreaks can occur in a nosocomial setting in which
most patients carry or display contamination with
ESBL-E. Indeed, our surveillance at the end of the
outbreak revealed that 46.3% (19/41) of patients were
colonized or infected with ESBL-E (Fig. 2). In multi-
focal outbreaks, efforts to detect the ESBL source will
sometimes end in failure.
Numbers of reports describing clonal outbreak arising
from a single source have been published [3–6]. ESBL-E
commonly reside in the intestine [10, 14]. Generally,
ESBL-E spread from the digestive tract via direct con-
tact, including that with medical items [15]. A hypoth-
esis explaining the unique infection source was not
conceivable in our cohort. Yet, in some cases, commonly
occurring outbreaks are due to non-clonal expansion. A
community-acquired methicillin-resistant Staphylococcus
aureus (MRSA) infection is increasing, and the same is
for ESBL-E. MRSA, both in the community and hospital
settings, colonizes and has low virulence [16]. And
ESBL-E can also colonize, and in such cases, it does not
become pathogenic in healthy individuals. Some ob-
servers in our hospital laboratories, nevertheless, empha-
sized on food-borne delivery as the source of outbreak
merely by referencing a rare report [12]. In accordance
with the decision of the infection control team (ICT),
they prepared a culture of frozen food in a backward
manner to the onset of the outbreak. No ESBL-E bacteria
were detected and the ICT ended to conclude community-
acquired ESBL-E is a main source of outbreak. Emerging
spreads of ESBL-producing bacteria in the community is
currently a dominant pattern of infection [4].
In this study, we characterized the different penetrance
patterns of the two species of ESBL-E. Our result sug-
gests that these two bacterial species obtained the ESBL
gene according to their microbiological properties [1].
PFGE demonstrated that 10 of 11 K. pneumoniae isolates
were similar in our analysis. K. pneumoniae isolates in
our cohort possessed the CTM-X-9 type of the ESBL
gene. blaCTM-X has been known to be easily mobilized
into plasmids in environmental bacteria [17]. At present,
the emergence of community-acquired ESBL-E infec-
tions is globally associated with the CTM-X type of
ESBL [4], especially with CTM-X-9 in East Asian coun-
tries including Japan [18]. CTX-M group ESBL genes are
assumed to have more facilitated spread than TEM and
SHV group ESBL genes under broad-spectrum anti-
microbial selection pressure. Indeed, CTX-M enzymes
have rapidly supplanted TEM and SHV group ESBL
genes [4]. Some microbiological advantages, which are
not yet understood, might possibly contribute to the
acquisition of ESBL genes in K. pneumoniae rather than
in E. coli. On the contrary, in E. coli, ESBL genes are
acquired through vector-transporting bacteriophages.
Among our cases, E. coli possessed various ESBL genes
categorized as TEM, SHV, and CTX-M types.
The digestive tract is the main reservoir for the colo-
nizers of community-acquired ESBL-E, especially E. coli
[15]. The probable mechanism of this variety of ESBL
genes is intraluminal transmission of resistance genes in
the individual gut. In our cohort, surveillance during the
outbreak identified E. coli among the colonized patients,
Fig. 3 Pulsed-field gel electrophoresis patterns of the genomic DNA
of extended-spectrum β-lactamas-producing Enterobacteriaceae The
left lane presents the molecular markers. a Klebsiella pneumoniae: The
unique strain numbers K10 and K11 denote control strains (labeled
as ©). b Escherichia coli: The unique strain numbers E8 and E9 denote
control strains (labeled as ©). The strain E3 was missing. Control
strains were prepared from clinically different isolates from
heterotopy/heterochrony sampling
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providing evidence of fecal carriage. Our results proved
that the E. coli strains had genetically variable ESBL
genes. Thereby, the E. coli outbreak was presumed to be
derived from originally community-acquired strains. In
general, ESBL genes are mainly transferred in a plasmid-
mediated manner. ESBL genes have been reported most
frequently in K. pneumoniae and E. coli [19]. Our specu-
lation is that the ability to acquire ESBL genes differs
among bacteria, and the penetrance of resistance is
strain-dependent. Specifically, ESBL-E outbreaks can
occur concurrently, as observed in this study. Subse-
quently, some non-clonal outbreaks can occur coinci-
dentally by the non-clonal strains derived from the
community colonizers. Back to the principle of infection
control, upon the hypothesis that patient populations in
which isolates are genetically similar most likely ac-
quired the organism via patient-to-patient transmission,
standard precaution and containment procedures should
be enforced irrespective of whether the outbreak is
clonal or non-clonal.
Our study has some limitations. First, this is a single-
institution observation study, and the sample size is small.
Hence, our observation may not represent a universal oc-
currence. Therefore, other similar clinical data should be
accumulated. We were exclusively interested in the differ-
ence in the penetrance of the ESBL gene during an out-
break in the clinical setting. The clonal or non-clonal
spread of ESBL-E is attributable to microorganisms and in-
dividual types of ESBL genes. Second, our study included
isolates from both infected and colonized subjects. This
protocol might confound the study conclusion. In this
study, we investigated the identification of infection source
including colonizing strains, in order to prevent an out-
break when the outbreak is spreading and initial action is
required immediately. Third, the last limitation of the study
concerns the comprehension of the control strains. We se-
lected some independent strains isolated in other wards at
different times as control samples for PFGE typing. How-
ever, one of the control strains could not be discriminated
from other K. pneumoniae strains. Despite some environ-
mental contamination, there was no evidence of transmis-
sion from patients known to be colonized or infected with
ESBL-producing K. pneumoniae and E. coli who were
discharged from the hospital or admitted to other wards.
Table 1 Typing of the extended-spectrum β-lactamase gene
a
Strain ID Patient ID Species TEM SHV CTX-M-1 CTX-M-2 CTX-M-8 CTX-M-9
K1 17868 Klebsiella pneumoniae (ESBL) ○
K10 2439551 Klebsiella pneumoniae (ESBL) ○ ○
K2 2607183 Klebsiella pneumoniae (ESBL) ○
K3 1001542 Klebsiella pneumoniae (ESBL) ○
K5 3082844 Klebsiella pneumoniae (ESBL) ○
K6 3083200 Klebsiella pneumoniae (ESBL) ○
K7 2014171 Klebsiella pneumoniae (ESBL) ○
K7 3052387 Klebsiella pneumoniae (ESBL) ○
K8 3073729 Klebsiella pneumoniae (ESBL) ○
K9 1824592 Klebsiella pneumoniae (ESBL) ○
K11 932245 Klebsiella pneumoniae (ESBL) ○
b
Strain ID Patient ID Species TEM SHV CTM-1 CTM-2 CTM-8 CTM-9
E1 2021190 Escherichia coli (ESBL) ○
E2 2535581 Escherichia coli (ESBL) ○
E3 1731148 Escherichia coli (ESBL) ○ ○
E4 2536875 Escherichia coli (ESBL) ○ ○
E5 2304303 Escherichia coli (ESBL) ○
E6 3065667 Escherichia coli (ESBL) ○
E7 2356293 Escherichia coli (ESBL) ○
E8 2362963 Escherichia coli (ESBL) ○ ○
E9 2568787 Escherichia coli (ESBL) ○ ○
Multiplex PCR results for TEM, SMV, CTX-M-1, CTX-M-2, CTX-M-8, and CTX-M-9 are presented. a) Klebsiella pneumoniae: All strains carried CTX-M-9, excluding one
control strain (K10) that carried SMV. b) Escherichia coli: Excluding E1, E2, E5, E6, and E7, all strains carried different types of ESBL genes. The strain identifier numbers
presented in the table were not linked to patient’s privacy and cannot compromise patient anonymity
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Conclusions
We observed that clonal and non-clonal outbreak of
ESBL-E corresponding to the difference of bacteria. We
were unable to identify the common source of the out-
break among the two organisms, i.e., K. pneumoniae and
E. coli, in the cohort. These two organisms would pos-
sibly transmit ESBL genes according to each bacteria’s
biological ability. This molecular microbiological differ-
ence did not appear in the mapping of ESBL-E spread,
but it did reflect organism-specific outbreaks whether
clonal or non-clonal. Our findings provide an outlook of
the concurrent expansion of clonal and non-clonal out-
breaks. Our cohort represents an endeavor to detect the
index case of the outbreak and clarify that a subject har-
boring ESBL-E is no longer essential in the era of wide-
spread ESBL-E dissemination in the community. Thus
far, we confirmed the importance of substantial standard
precautions in the background of the expansion of
multidrug-resistant organisms in the community.
Additional file
Additional file 1: Table S1. Antibiogram of extended-spectrum β-
lactamase-producing Enterobacteriaceae. The susceptibility of each strain
for the given antibiotics is presented in the table as the susceptibility titer
number. The number are shown as minimum inhibitory concentration
(MIC) μg/mL. Resistance is indicated by bold characters. Different clones
from the same specimen in the same individual were numbered using
subnumbers, e.g., XX_1 and XX_2. We classified the clones into resistance
groups as follows: Group A, sensitive to all antibiotics excluding cephalosporins
(e.g., CAZ); group B, resistant to PIPC and cephalosporins; group C, resistant to
quinolones and cephalosporins; and group D, resistant to all antibiotics
excluding carbapenems. Based on our original grouping criteria, the
strains could be categorized to four resistance groups. We categorized
the strains in the four groups and attempted to comprehend the
clonality of each bacterium. (a) Klebsiella pneumoniae: K3, K4, K8, and
K11 were classified into group A; K5, K7, and K9 into group B; K2 and
K10 into group C; and K6 into group D. (b) Escherichia coli: E2 was categorized
in group A, and the other strains were categorized in group D. Thus,
the pattern of antimicrobial susceptibility was more variable for K.
pneumoniae than for E. coli. (The control strains are remarked as ©.).
The strain identifier numbers presented in the table were not linked to
patient’s privacy and cannot compromise patient anonymity. (DOCX 19 kb)
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